ArticleThe Lancet. Oncology2020

Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

Yukiya Narita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.